Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Angioplasty and stents treat renal arteries:

This article was originally published in Clinica

Executive Summary

Endovascular treatments are as effective as bypass for renovascular hypertension but can be performed at a lower cost, US researchers report in the August edition of Radiology. In a retrospective analysis of 130 patients, researchers at the Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, found that stenting had the highest success rate at 98%, while angioplasty and bypass both exceeded 90%. However, bypassing cost $15,393 versus $1,402 for angioplasty and $2,573 for stenting. Complication rates were 13%, 16% and 38% for angioplasty, stenting and bypass respectively.

You may also be interested in...



AAM Criticizes Lower Health Care Costs Act

Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.

USCMA Revision Worsens Innovator Woes In Canada

Stripping the revised USMCA deal of provisions to strengthen IP rights for biologics will worsen market difficulties in Canada caused by changes to the drug pricing regime, says industry.

A Steady Year For The Top Tier In Pharma Ahead Of Major Upheaval

Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.

Topics

UsernamePublicRestriction

Register

MT079194

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel